National Breast Cancer and Lymphedema Registry
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Stanley Rockson
- Enrollment
- 549
- Locations
- 1
- Primary Endpoint
- Preemptive diagnostic and treatment strategies
- Status
- Terminated
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of the National Breast Cancer Lymphedema Registry is to collect health information in order to study the lymphedema as a complication of breast cancer treatment. The investigators hope to learn whether early diagnosis will help to prevent lymphedema or, if it does occur, to reduce the severity.
Detailed Description
Historically, breast cancer-associated lymphedema has been relatively ignored, with mis-diagnosis, late diagnosis, and failure to treat. The condition has a measurable, substantial impact on patient function and perceived quality of life (QOL). Recent pilot studies suggest that interventions that are designed to facilitate early diagnosis and preventive strategies have a major impact on the incidence and severity of disease burden. This registry is designed to prospectively capture the relevant data to document the impact of preemptive diagnostic and treatment strategies.
Investigators
Stanley Rockson
Allan and Tina Neill Professor of Lymphatic Research and Medicine
Stanford University
Eligibility Criteria
Inclusion Criteria
- •Breast cancer survivorship
Exclusion Criteria
- •Age \< 18 years old
Outcomes
Primary Outcomes
Preemptive diagnostic and treatment strategies
Time Frame: Each enrolled patient will be followed for an average of 1 year
The methods for lymphedema surveillance and detection will be correlated to the new appearance of lymphedema in this cohort of breast cancer survivors. We will also assess severity of lymphedema and responsiveness to treatment strategies.